European Medical Solutions (ALEMS.BR)
EUR 4.9
(1.07%)
EUR 4.9
(1.07%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.93 Million EUR | 39.49% |
| 2022 | 9.98 Million EUR | -4.27% |
| 2021 | 10.43 Million EUR | 272.04% |
| 2020 | 2.8 Million EUR | 85.2% |
| 2019 | 1.51 Million EUR | 123.84% |
| 2018 | -6.35 Million EUR | -282.65% |
| 2017 | -1.66 Million EUR | 87.19% |
| 2016 | -12.95 Million EUR | -3230.59% |
| 2015 | -389 Thousand EUR | 95.39% |
| 2014 | -8.44 Million EUR | -2244.72% |
| 2013 | -360 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 13.51 Million EUR | 35.29% |
| 2023 Q4 | 13.93 Million EUR | 3.11% |
| 2023 FY | 13.93 Million EUR | 39.49% |
| 2022 Q4 | 9.98 Million EUR | -12.29% |
| 2022 Q2 | 11.38 Million EUR | 316.19% |
| 2021 Q2 | 2.64 Million EUR | -5.74% |
| 2021 Q4 | 2.73 Million EUR | 3.52% |
| 2020 Q4 | 2.8 Million EUR | 10.57% |
| 2020 Q2 | 2.53 Million EUR | 67.5% |
| 2019 Q2 | -1.16 Million EUR | 81.63% |
| 2019 Q4 | 1.51 Million EUR | 229.73% |
| 2018 Q2 | -13.02 Million EUR | -684.46% |
| 2018 Q4 | -6.35 Million EUR | 51.22% |
| 2017 Q4 | -1.66 Million EUR | 78.76% |
| 2017 Q2 | -7.81 Million EUR | 39.67% |
| 2016 Q2 | -19 Million EUR | -4784.58% |
| 2016 Q4 | -12.95 Million EUR | 31.81% |
| 2015 Q4 | -389 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nicox S.A. | 13.89 Million EUR | -0.266% |
| FERMENTALG | 4.19 Million EUR | -232.244% |
| argenx SE | -1.83 Billion EUR | 100.759% |
| BioSenic S.A. | 28.04 Million EUR | 50.324% |
| Celyad Oncology SA | -6.1 Million EUR | 328.302% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 155.475% |
| Onward Medical N.V. | -12.89 Million EUR | 208.043% |
| Oxurion NV | 10.71 Million EUR | -30.075% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | 5165.818% |
| Financière de Tubize SA | 78.62 Million EUR | 82.282% |
| UCB SA | 2.17 Billion EUR | 99.36% |